Davita Inc vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while JPMorgan Diversified Return International Eqty ETF trades at $73.03 (market cap $378.77M). The key difference: Davita Inc is far larger — about 29.8× JPMorgan Diversified Return International Eqty ETF's market cap, and Davita Inc is more actively traded (582,204 versus 13,861). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and JPMorgan Diversified Return International Eqty ETF for 120 Days on average.
| DVA | JPIN | |
|---|---|---|
Market Cap | $11.29B | $378.77M |
Volume | 582,204 | 13,861 |
Sector | Health | — |
52-Week High | $240.96 | $77.80 |
52-Week Low | $103.87 | $64.96 |
Typical Hold Time | 114 Days | 120 Days |
Enterprise Value | $24.01B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
JPIN trades at $73.03 with minimal daily movement (+0.12%). Technical indicators signal strong bearish momentum across moving averages and oscillators, though RSI levels suggest potential oversold conditions. The ETF maintains a strategic focus on international value stocks but lacks current fundamental ratio data. Recent dividend activity shows a $0.51 distribution scheduled for September 2026.
The bearish technical setup dominates the near-term outlook, with resistance clustered at $74. Investment appeal hinges on international equity market recovery and the ETF's value strategy execution. Key risks include global market volatility and currency fluctuations affecting international holdings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →